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An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals is needed to
guide vaccine design and immunization strategies. Here we used a large panel of 44 HIV-1 envelope variants
(subtypes A, B, and C) to evaluate the presence of broadly neutralizing antibodies in serum samples obtained
3 years after seroconversion from 40 women enrolled in the CAPRISA 002 acute infection cohort. Seven of 40
participants had serum antibodies that neutralized more than 40% of viruses tested and were considered to
have neutralization breadth. Among the samples with breadth, CAP257 serum neutralized 82% (36/44 variants)
of the panel, while CAP256 serum neutralized 77% (33/43 variants) of the panel. Analysis of longitudinal
samples showed that breadth developed gradually starting from year 2, with the number of viruses neutralized
as well as the antibody titer increasing over time. Interestingly, neutralization breadth peaked at 4 years
postinfection, with no increase thereafter. The extent of cross-neutralizing activity correlated with CD4 T cell
decline, viral load, and CD4 T cell count at 6 months postinfection but not at later time points, suggesting
that early events set the stage for the development of breadth. However, in a multivariate analysis, CD4 decline
was the major driver of this association, as viral load was not an independent predictor of breadth. Mapping
of the epitopes targeted by cross-neutralizing antibodies revealed that in one individual these antibodies
recognized the membrane-proximal external region (MPER), while in two other individuals, cross-neutralizing
activity was adsorbed by monomeric gp120 and targeted epitopes that involved the N-linked glycan at position
332 in the C3 region. Serum antibodies from the other four participants targeted quaternary epitopes, at least
2 of which were PG9/16-like and depended on the N160 and/or L165 residue in the V2 region. These data
indicate that fewer than 20% of HIV-1 subtype C-infected individuals develop antibodies with cross-neutral-
izing activity after 3 years of infection and that these antibodies target different regions of the HIV-1 envelope,
including as yet uncharacterized epitopes.
Neutralizing antibodies are thought to be crucial in the pro-
tective immune response against many viral infections, yet
their role in HIV-1 infection remains controversial. During
natural infection, they appear to have little impact on acute
viremia, as they arise too late and the virus readily escapes
type-specific neutralizing antibodies (35, 41, 42, 55). However,
passive transfer of broadly neutralizing monoclonal antibodies
(MAbs) has proven to be protective in nonhuman primate
models (2, 11, 17, 18, 27, 28, 52), supporting the hypothesis that
a vaccine capable of inducing this type of antibodies is likely to
be effective. Despite rigorous efforts, designing an immunogen
capable of inducing broadly neutralizing antibodies has so far
not been feasible. Recently, researchers have turned their at-
tention to understanding the factors associated with the pres-
ence of broadly cross-neutralizing antibodies, which develop in
a subset of chronically HIV-1-infected individuals. A number
of reports from an assortment of different cohorts have found
that the duration of infection, viral load, CD4 T cell count,
and/or viral diversity is associated with the development of
neutralization breadth (10, 37, 44).
The B cell response to HIV-1 infection first appears within
8 days of detectable viremia and initially comprises antigen-
antibody complexes (47). This is followed by the detection of
circulating anti-gp41 antibodies 5 days later, with anti-gp120
antibodies delayed a further 14 days and targeting primarily
the V3 loop. Autologous neutralizing antibodies develop
months later (15) and target the variable regions via potent but
extremely type-specific neutralizing antibodies (22, 33, 41, 55).
Recent data from our laboratory suggest that during the first
year of HIV-1 subtype C infection, within a single individual, a
limited number of antibody specificities mediate autologous
neutralization (34). These arise sequentially and show tempo-
ral fluctuations as escape occurs. After years, antibodies with
cross-neutralizing potential appear in as many as one-third of
chronically infected individuals and target more conserved re-
gions of the HIV-1 envelope (46).
An increasing number of studies have focused on mapping
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the antibody specificities responsible for the cross-neutralizing
activity found in selected HIV-1-positive plasmas (3, 16, 25, 44,
45, 54). Using a variety of methodologies, it has been estab-
lished that some of these neutralizing antibodies recognize
epitopes in the context of monomeric gp120, e.g., the CD4 and
coreceptor binding sites. In a few cases, the cross-neutralizing
activity could be attributed to antibodies recognizing linear
epitopes in the membrane-proximal external region (MPER)
of gp41 (14, 45). However, many of the antibody specificities
responsible for cross-neutralization could not be matched to
known epitopes in these studies. More recently, it has become
apparent that a quaternary epitope at the tip of the trimeric
envelope structure, involving the V2 and V3 loop, is frequently
the target of cross-neutralizing antibodies (34, 53, 54). Another
cross-reactive specificity, involving the N332 residue in the C3
region at the base of the V3 loop, was also described recently,
but the epitope has yet to be defined. Taking these data to-
gether, it appears that a limited number of neutralizing anti-
body specificities are responsible for the broad neutralizing
activity in plasma samples (54). Isolation of MAbs from these
individuals may delineate important targets on the HIV-1 en-
velope glycoprotein and thus inform vaccine design. Indeed,
naturally occurring broadly neutralizing MAbs, such as b12,
2G12, 4E10, and 2F5 (6), have been crucial reagents for many
years, and the more recently isolated MAbs VRC01 and PG9/
PG16 (53, 56) are providing new insights into the native enve-
lope structure. However, the mechanism by which these anti-
bodies develop and why this occurs only in some individuals
are not clear. Defining when cross-neutralizing antibodies
emerge might provide important clues as to their nature and
how to elicit them. For this purpose, suitable cohorts of HIV-
infected individuals with antibodies able to cross-neutralize
heterologous viruses need to be identified and longitudinal
samples assessed.
Previously, we reported on the development of early type-
specific neutralizing antibodies in the CAPRISA acute infec-
tion cohort (15). While autologous neutralizing antibodies
were found in all individuals from 3 to 12 months postinfection,
little heterologous neutralizing activity was detected in the 14
participants analyzed at 12 months of infection. Here we ex-
tended this analysis to 40 participants from the same cohort
who had reached at least 3 years postinfection to evaluate the
kinetics of the development of cross-neutralizing antibodies.
We also analyzed the association between neutralization
breadth and clinical factors, such as viral load and CD4 T cell
count, and explored the epitopes targeted by these cross-reac-
tive antibodies. Our results suggest that cross-neutralizing an-
tibodies targeting different regions on the HIV-1 envelope
develop over many years, with low CD4 T cell counts and
high viral loads in early infection favoring their emergence.
MATERIALS AND METHODS
Study subjects. Plasma and serum samples were obtained from participants in
the CAPRISA acute infection cohort (CAPRISA 002), established in 2004 in
Durban and Vulindlela, South Africa. Participants in Durban were part of a
prospective study of 245 high-risk HIV-negative women who were followed up
for subsequent identification of HIV seroconversion (51). A total of 62 women
(28 from the HIV-negative cohort and 34 from other seroincidence cohorts) who
had a reactive HIV antibody test within 5 months of a previously negative result
or detection of HIV-1 RNA by PCR (Roche Amplicor v1.5) in the absence of
HIV antibodies were enrolled. Thereafter, participants were monitored and
referred to the antiretroviral (ARV) therapy initiation program when their
CD4 T cell counts dropped below 350 cells/l on 2 separate occasions. They
were initiated on ARV therapy only once their CD4 T cell counts fell below 200
cells/l or other signs suggestive of WHO stage 4 disease were evident (2004
National Antiretroviral Treatment Guidelines). After the implementation of the
2010 South African Antiretroviral Treatment Guidelines, ARV treatment could
be initiated with CD4 T cell counts of up to 350 cells/l in Mycobacterium
tuberculosis-coinfected individuals. Samples were collected and stored at least
every 3 months during chronic infection. This study received ethical approval
from the University of Witwatersrand, University of KwaZulu-Natal, and Uni-
versity of Cape Town.
Envelope clones. Envelope genes used in this study were either cloned previ-
ously in our laboratory (15) or obtained from the NIH AIDS Research and
Reference Reagent Program. The ConC plasmid, carrying an envelope gene
representing the consensus of all HIV-1 subtype C sequences deposited in the
Los Alamos database by 2001, was obtained from Feng Gao (20). Mutations
were introduced into envelope clones by use of a QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). Plasmids encoding HIV-2/HIV-1
MPER chimeras were obtained from George Shaw (15).
Neutralization assays. Neutralization was measured as a reduction in lucifer-
ase gene expression after a single round of infection of JC53bl-13 cells, also
known as TZM-bl cells (NIH AIDS Research and Reference Reagent Program),
with Env-pseudotyped viruses (32). Titer was calculated as the reciprocal plasma/
serum dilution causing a 50% reduction of relative light units (ID50).
gp120 production and isolation. The gp120-encoding region of the ConC
envelope was inserted into the pPPI4 expression vector (Progenics Pharmaceu-
ticals, Inc., Tarrytown, NY) (4). The D368R and I420R mutations were intro-
duced by site-directed mutagenesis. The resulting constructs were transfected
into 293T cells seeded in a HYPERFlask (Corning Inc., Lowell, MA) by using
Fugene (Roche Applied Science, Indianapolis, IN). Cell supernatants were col-
lected after 48 h and every second day thereafter for another three harvests.
gp120 was isolated using Galanthus nivalis lectin agarose matrix (Sigma-Aldrich,
St. Louis, MO) and eluted with 1 M methyl--D-manno-pyranoside (Sigma-
Aldrich). Remaining protein contaminants were eliminated through ion-ex-
change chromatography using FastFlow Q-Sepharose (GE Healthcare Life Sci-
ence, Piscataway, NJ) equilibrated in phosphate-buffered saline (PBS) and
reconstituted in 2 M NaCl–PBS. The pure protein was collected in the flow-
through, washed in PBS, and concentrated to 5 mg/ml. The purity of the final
gp120 preparation was tested by subjecting 10 g of protein to SDS-PAGE.
Protein preparations with a purity of 99% were used in subsequent experi-
ments.
Adsorption of anti-gp120 antibodies from plasma. Adsorption of plasma anti-
gp120 antibodies, using gp120 covalently coupled to tosyl-activated magnetic
beads, was done as previously described (16, 25). The depletion of anti-gp120
antibodies was evaluated by enzyme-linked immunosorbent assay (ELISA) as
described elsewhere (25).
Statistical analysis. Statistical analysis was performed using GraphPad Prism
5.0 and SAS software, version 9.1.3 (SAS Institute Inc., Cary, NC). Friedman’s
test was performed for pairwise comparisons of the percentages of viruses neu-
tralized for each subtype (A, B, and C). The same data were analyzed using the
Kruskal-Wallis rank sum unpaired test. A Wilcoxon matched-pair test was used
to compare the medians of viruses neutralized among CAPRISA viruses and
Zambian viruses.
The area under the curve (AUC) for viral loads between 6 months and 3 years
of infection was calculated using 400 copies/ml as a baseline, which is the limit of
detection of the viral load quantification assay used. Spearman rank tests were
used to determine the correlation between neutralization breadth and all factors
analyzed.
Univariate and multivariate linear regression models were used to study the
factors associated with neutralization breadth. First, univariate models were
fitted one at a time with each of the predictors, and then potential predictors
were analyzed in two multivariate logistic regression models. Model 1 evaluated
the significance of each predictor among all the viral load measurements, while
model 2 included only the 6-month viral load and CD4 T cell decline (differ-
ence between preinfection and 6-month CD4 T cell counts) as predictors.
A proportional hazard regression model and Kaplan-Meier survival analysis
were performed for the time between infection and a CD4 T cell count of 200
cells/l and/or antiretroviral therapy initiation (whichever came first). A log rank
P value test was used to determine differences between participants who devel-
oped cross-neutralizing antibodies and those who did not but had comparable
viral loads. Those who did not initiate treatment were censored at their last visit.
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RESULTS
Broadly cross-neutralizing antibodies develop in a small
proportion of HIV-1-infected individuals. Previous studies
have demonstrated that the development of cross-neutralizing
antibodies during HIV-1 infection is greatly delayed, appear-
ing in only a subset of individuals (45). To assess the extent of
heterologous neutralization in the CAPRISA 002 cohort, se-
rum samples from participants who had documented HIV-1
infection for 3 years were assayed. Of the 62 women enrolled,
9 were referred to and initiated on antiretroviral treatment, 3
were lost to follow-up, and 2 suffered HIV-unrelated deaths
before reaching 3 years of infection. Of the remaining 48 in-
dividuals, 40 reached 3 years postinfection by June 2010 with-
out requiring antiretroviral treatment and were included in this
study. The median CD4 T cell count of the study group after
3 years of infection was 442 cells/l, and the median viral load
was 15,700 copies/ml. Seven of the study participants were
classified as rapid progressors and five as controllers, with the
rest being considered intermediate progressors (Fig. 1).
All serum samples were assayed using the TZM-bl neutral-
ization assay against various standard virus reference panels.
These included 6 subtype A (5), 12 subtype B (23), and 12
subtype C (24) envelope-pseudotyped viruses. In addition, 12
pseudoviruses isolated from some of the CAPRISA partici-
pants during the acute phase of infection (15), as well as the
reference strains ConC and Du151.12 (subtype C), were used.
Samples were scored as positive if a virus was neutralized at
titers above 1:45. Percent breadth was calculated based on the
number of viruses in all panels that each serum sample neu-
tralized (excluding autologous titers).
There was a wide range of activities, with most of the 3-year
sera lacking substantial heterologous activity against tier 2 vi-
ruses (Fig. 1). However, samples from a few individuals
showed extensive cross-neutralization against viruses of differ-
ent subtypes, while on the other extreme, some sera showed no
activity. Based on the percent neutralization, participants were
categorized into 3 groups. Samples from 7 individuals able to
neutralize more than 40% of the panel were considered to
have neutralization breadth (group 1). Those with less than
10% activity (n  19 [48%]) were considered to have no
breadth (group 3), and those with activities between these
values (n  14 [35%]) were considered to have intermediate
breadth (group 2). Among group 3 individuals, samples from 3
participants (CAP45, CAP88, and CAP221) did not neutralize
any of the heterologous viruses tested, while those from 10
others neutralized only 1 to 3 viruses, often at low titers.
Among the individuals with breadth, CAP257 samples neutral-
ized 36/44 (82%) panel members, while CAP256 samples neu-
tralized 33/43 viruses (77%, excluding the autologous virus),
the latter with exceptionally high titers against some viruses.
Indeed, titers of heterologous neutralization varied greatly,
possibly due to differences in the exposure or structural hetero-
geneity of the epitopes targeted by these antibodies. Alterna-
tively, these polyclonal serum samples contained mixtures of
antibodies, with each targeting a different virus. Autologous
titers were detected in all cases, as one might expect, given that
autologous viruses were isolated at earlier time points from
these individuals.
All viruses in the 44-member panel were neutralized by at
least one serum sample. The most resistant viruses to these
sera were TRJO4551.58 (subtype B), REJO4541.67 (subtype
B), and Q461.e2 (subtype A), while the most sensitive viruses
were CAP85.9 (subtype C), ZM109F.PB4 (subtype C), and
Q23.17 (subtype A). Interestingly, there was a strong correla-
tion between the ability to neutralize the ConC virus (often at
high titers) and the development of neutralization breadth
(P  0.0001).
Analyzed all together, sera from CAPRISA participants
more frequently neutralized viruses from the subtype C panels
(23%) than subtype A (15%) or B (14%) viruses. This com-
parison was statistically significant using a Friedman test, with
a P value of 0.0003. However, this effect was clearly driven by
a subset of the sera that had subtype-specific neutralization, as
an unpaired comparison lacked statistical significance
(Kruskal-Wallis test; P  0.1213).
Given that many of the subtype C viruses used in this study
were from the CAPRISA cohort, we evaluated whether these
viruses were better neutralized by serum samples from
CAPRISA participants. Thus, we compared the percentage of
viruses neutralized and the geometric mean titer obtained with
each of the 40 serum samples against the 14 CAPRISA viruses
with those for the 7 Zambian viruses from the subtype C tier 2
panel. No statistically significant differences were observed in
Wilcoxon matched-pair tests between the percentages of vi-
ruses neutralized (P  0.2462) or the geometric mean titers
(P  0.2862) for these two groups of viruses (data not shown),
suggesting that CAPRISA sera did not preferentially neutral-
ize epidemiologically related viruses obtained from within the
same cohort.
Viral load at set point and CD4 T cell decline strongly
correlate with the development of breadth. Previous studies
have found an association between viral load and/or CD4 T
cell count and the presence of cross-neutralizing antibodies
(10, 37, 44). Here we analyzed the correlation between the
percentage of viruses neutralized by each individual (as a mea-
surement of neutralization breadth) and the viral load and
CD4 T cell count at 6, 12, and 36 months postinfection (Fig.
2). In addition, as a measurement of total antigenic exposure,
we calculated the area under the curve for the viral loads over
time from 6 months to 3 years of infection (viral load AUC).
These analyses revealed a significant correlation between the
viral load at set point (6 months postinfection) and the per-
centage of viruses neutralized at 3 years (Fig. 2A). Similarly, a
negative correlation was found between the CD4 T cell count
at 6 months postinfection and the development of breadth
(Fig. 2D). However, no correlation was found between neu-
tralization breadth and these two factors at later time points
(Fig. 2B, C, E, and F). Furthermore, no significant correlation
was observed between neutralization breadth and the viral load
AUC (Fig. 2G), suggesting that the antigen load at a particular
time postinfection, not total antigenic exposure, predisposes
individuals toward the development of breadth. These corre-
lations were confirmed using more robust statistical analyses
(Table 1). Thus, while a univariate model analysis showed that
viral loads at 6 months and 12 months and the AUC were
significantly associated with neutralization breadth, a multivar-
iate analysis revealed that the 6-month viral load was the major
driver of this association. For every 1-log increase in viral load
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at 6 months, the percentage of cross-neutralization increased
by 12.4% (P  0.002).
Interestingly, the correlation between CD4 T cell count
prior to infection and neutralization breadth showed a positive
trend, although it was not statistically significant (Fig. 2H). Of
note, preinfection CD4 T cell counts were available for only
21 participants in the seronegative cohort, which included 3 of
the 7 individuals with the broadest cross-neutralizing activities.
These data are in stark contrast to the negative slope of the
CD4 T cell count at 6 months postinfection (Fig. 2D). Fur-
thermore, the decline in CD4 T cell number upon HIV-1
infection, measured as the difference between CD4 T cell
counts preinfection and at 6 months postinfection, strongly
correlated with the development of heterologous neutraliza-
tion (r  0.52; P  0.0144) (Fig. 2I). This was confirmed in a
univariate model analysis (Table 1). Given the existing corre-
lation between viral load and CD4 T cell decline, both vari-
ables were fitted into a second multivariate model, which re-
vealed a significant association between the development of
breadth and CD4 T cell decline (P  0.0474) but not viral
load (Table 1).
As shown above, the development of breadth was associated
with factors such as high viral load and steep CD4 T cell
decline in early infection, which are well known markers of
disease progression (12, 13, 29). Of the 40 participants tested
for heterologous neutralization, 11 were initiated on treatment
during the course of this study, including 5 of the 7 women in
group 1. To investigate the potential relationship between the
development of neutralization breadth and disease progres-
sion, a Kaplan-Meier survival analysis was performed from the
time of infection until the first CD4 T cell count below 200
cells/l or therapy initiation as a marker of clinical AIDS.
FIG. 2. Factors correlated with the development of cross-neutralizing antibodies. The percentage of viruses neutralized by each serum was
correlated with the 6-month (set point), 12-month, and 36-month (contemporaneous) viral loads (VL) (A, B, and C) and CD4 T cell counts (D,
E, and F). Neutralization breadth was also correlated using the viral load AUC from 6 to 36 months postinfection (G), the preinfection CD4 T
cell count (H), and the decline in CD4 T cell count between preinfection and 6 months postinfection (I). Each correlation was analyzed using
a Spearman nonparametric test. The number of pairs (N) and P value for each correlation are shown. Statistically significant P values are marked
with asterisks.
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Because of the link between viral load and disease progression,
we excluded participants with low viral loads from this analysis
and included only the 22 individuals for whom the viral load
AUC exceeded 5 million copies per ml. These were divided
into two groups: 7 participants with cross-neutralizing antibod-
ies (BCN) and 15 participants without breadth but with similar
viremia (no BCN) at 3 years postinfection (Fig. 3). There were
no significant differences between the median viral loads and
CD4 T cell counts of both groups at all time points. A Cox
proportional hazard model showed that those who developed
breadth had a hazard ratio of 1.04 (95% confidence interval
[95% CI], 0.32 to 3.34) and a log rank test P value of 0.9508.
These results indicated that the development of cross-neutral-
izing antibodies did not preclude or promote disease progres-
sion.
Evolution of cross-neutralizing antibodies in individuals
with the greatest breadth. Early serum samples from the 7
individuals with the greatest neutralization breadth (group 1)
were assayed against all the viruses neutralized by the 3-year
samples with titers above 1:100. On average, sera from 13 time
points (range, 10 to 19 time points) over the first 3 years of
infection were included. The longitudinal neutralization pro-
files against both autologous and sensitive heterologous viruses
for each of the 7 participants are shown in Fig. 4. As described
previously (15), antibodies to the infecting virus appeared
within months of infection and titers remained high over 3
years. This suggested that despite multiple cycles of escape,
sufficient neutralizing determinants remained on the infecting
virus to stimulate new autologous specificities. Some of these
new specificities acquired the ability to neutralize heterologous
viruses of different subtypes (Fig. 4 [viruses from different
subtypes are color coded]).
Analysis of the individual neutralization patterns showed
that in one case (CAP206), the neutralizing activities against
the majority of viruses occurred simultaneously (at 81 weeks
postinfection), suggesting that a single dominant antibody
specificity with cross-neutralizing activity emerged at this time
point. Interestingly, this response waned at 107 weeks but
reappeared later, targeting the same viruses (Fig. 4A). In par-
ticipants CAP177 and CAP255, heterologous activity appeared
mostly during the second year of infection (52 to 90 weeks
postinfection), with titers reaching a plateau thereafter (Fig.
4B and C). This might indicate affinity maturation of existing
antibodies resulting in increased potency and breadth. The
same can be said for the remaining four individuals, in whom
the neutralizing activity increased gradually over an extended
period (Fig. 4D, E, F, and G). Alternatively, the cross-neutral-
izing activity in these four participants might involve the ap-
pearance of new specificities which target different epitopes on
different viruses. Some of these new antibodies appeared to be
subtype specific, as the early sera from participants CAP248,
CAP255, CAP256, and CAP257 preferentially neutralized sub-
type C viruses, with cross-subtype neutralization appearing at
later stages (Fig. 4).
Heterologous neutralization increases over time, peaking at
4 years of infection. The above data from the 7 individuals in
group 1 suggested that neutralization breadth continued to
increase over 3 years of infection. In order to more fully ex-
plore the dynamics of the development of breadth, we tested
TABLE 1. Factors correlated with neutralization breadth
Variable
Univariate model Multivariate model 1 Multivariate model 2
Estimate (95% CI) P valuea Estimate (95% CI) P valuea Estimate (95% CI) P valuea
Viral load
6 mo 0.11 (0.077, 0.143) 0.0020 0.124 (0.071, 0.178) 0.0259 0.032 (0.008, 0.073) 0.4308
12 mo 0.077 (0.040, 0.114) 0.0437 0.005 (0.065, 0.055) 0.9366
36 mo 0.044 (0.008, 0.080) 0.2219 0.045 (0.096, 0.006) 0.3836
Viral load AUC 0.080 (0.043, 0.117) 0.0389 0.026 (0.045, 0.098) 0.7145
Preinfection CD4 countb 0.016 (0.008, 0.024) 0.0710
CD4 declineb 0.024 (0.015, 0.032) 0.0094 0.021 (0.030, 0.011) 0.0474
CD4 count
6 mo 0.029 (0.046, 0.012) 0.0998
12 mo 0.024 (0.041, 0.007) 0.1564
36 mo 0.021 (0.037, 0.005) 0.1923
a Statistically significant P values are shown in bold.
b Data are available for only 21 of the 40 study participants.
FIG. 3. Kaplan-Meier analysis of time from seroconversion until
ARV initiation for CAPRISA participants with and without neutral-
ization breadth. Study participants with similar viral loads were segre-
gated based on their cross-neutralizing activity at 3 years postinfection,
into BCN (group 1) (Fig. 1) and no BCN (groups 2 and 3) groups. A
Cox proportional hazard analysis was used to compare the two groups
based on time of infection until the first CD4 T cell count below 200
cells/l or therapy initiation.
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sera from all 40 individuals at 1, 2, and 3 years postinfection. In
addition, samples were collected from 27 of the 40 participants
at 4 years of infection (7 participants, including CAP8 and
CAP255, had initiated antiretroviral therapy, and 6 had not yet
reached 4 years of infection). By 5 years of infection, samples
from 12 participants were available (3 participants, including
CAP256 and CAP257, started treatment before 5 years of
infection, and 12, including CAP177, had not yet reached this
time point). Individual CAP206 was initiated on treatment
shortly after 5 years of infection, while subject CAP248 re-
mained therapy naive over the course of the study. For this
analysis, we used a smaller panel of 12 viruses, which included
4 viruses of each subtype (A, B, and C). We found a good
correlation between the percentages of viruses neutralized us-
ing the reduced panel and the full panel of 44 viruses with sera
from 3 years postinfection (R2  0.9012; P  0.0001).
The heterologous neutralizing activity increased gradually
over time for the first 4 years (Fig. 5A), consistent with earlier
reports that neutralization breadth was associated with dura-
tion of infection (44). The titers at which viruses were neutral-
ized also increased over this period. An analysis of the 27
individuals at 4 years indicated that in addition to those pre-
viously shown to have neutralization breadth (i.e., CAP177,
CAP256, and CAP257), 2 other individuals (CAP37 and
CAP267) showed a breadth of 40% of viruses neutralized at
this time point (Fig. 5B). CAP37 also showed more than 40%
neutralization at 3 years of infection, reflecting minor differ-
ences in the 2 viral panels used for Table 1 and Fig. 5. Most of
the other individuals showed slight increases in breadth be-
tween 3 and 4 years, but all remained below 40%. At 5 years of
infection, no additional samples were found to have developed
neutralization breadth. Only CAP206 and CAP248, previously
shown to have breadth, had neutralization percentages above
40% at this time (Fig. 5C). Indeed, there appeared to be no
increase in heterologous neutralization between 4 and 5 years
of infection in this small subset, even among those with
breadth, suggesting that no new further maturation or new
specificities were generated after 4 years of infection.
Mapping the antibody specificities in broadly neutralizing
plasmas. We previously reported the presence of anti-MPER
antibodies at high titers (ID50s above 1:1,000) in participant
CAP206 (15). Removal of these anti-MPER antibodies using
MPER peptide-coated beads resulted in a significant loss of
neutralizing activity against most heterologous viruses. Plas-
mas from CAP248, CAP255, and CAP257 had undetectable
neutralization titers against the HIV-2/HIV-1 MPER chimeric
virus, while plasmas from CAP8, CAP177, and CAP256 had
low anti-MPER neutralization titers, of 1:73, 1:280, and 1:274,
respectively. The removal of these low-titer anti-MPER anti-
bodies did not affect heterologous neutralization (data not
shown).
FIG. 4. Kinetics of development of heterologous neutralization in individuals with breadth. Sequential serum samples from 0 to 3 years of
infection (10 to 19 samples) from all 7 participants with breadth were tested against all the viruses previously shown to be sensitive to the 3-year
plasma samples. The ID50 titers versus weeks postinfection (p.i.) are represented for each virus, with the autologous viruses shown in solid black,
subtype C viruses in red, subtype B viruses in blue, and subtype A viruses in green. The time points when detectable heterologous activity emerged
are indicated using dashed vertical lines, with the number of additional viruses neutralized displayed above. The viral loads over time are shown
as dashed black curves.
FIG. 5. Development of cross-neutralizing antibodies over 5 years
of infection. The sera obtained at 1, 2, 3, 4, and 5 years of infection
were tested for neutralization against a panel of 12 viruses of subtypes
A, B, and C (4 of each subtype). The percentage of viruses neutralized
was calculated for each sample. (A) Percentages of individuals capable
of neutralizing more than 80%, 40 to 80%, 1 to 40%, and none of the
12 viruses at 5 different time points. (B and C) Percentages of viruses
neutralized over time for the 15 and 12 participants that reached 4 and
5 years postinfection, respectively.
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To further explore the specificities of the cross-neutralizing
antibodies in the other 6 individuals, anti-gp120 antibodies in
the 3-year postinfection plasmas were removed using magnetic
beads coated with recombinant ConC gp120. More than 97%
of the gp120-binding antibodies were depleted in an ELISA
(Fig. 6A). For CAP177 and CAP255, neutralizing activities
against at least three viruses were significantly decreased by the
removal of anti-gp120 antibodies (Fig. 6B). Since no effect was
seen with the samples from the other four individuals, we
purified ConC trimers by gel exclusion chromatography and
immediately used these to coat magnetic beads for adsorption
experiments. However, despite the removal of most gp145-
binding antibodies (Fig. 6A), this protein also failed to adsorb
significant amounts of the neutralizing activity in plasmas from
CAP8, CAP248, CAP256, and CAP257 (Fig. 6C), suggesting
that neutralizing antibodies in these four plasmas recognized
epitopes only apparent on the quaternary structure of the
envelope glycoprotein.
Further experiments were performed to determine the
epitope(s) within gp120 that was recognized by the CAP177
and CAP255 neutralizing antibodies. We found that gp120
mutated in the CD4 (D368R) or coreceptor (I420R) binding
site effectively removed the heterologous activity (Fig. 7A),
suggesting that the epitopes recognized by these plasmas do
FIG. 6. Adsorption of neutralizing antibodies using recombinant envelope proteins. Plasmas obtained at 3 years postinfection were adsorbed
using recombinant ConC monomeric gp120- or trimeric gp145-coated beads. Blank beads were used as a negative control. (A) Depleted plasmas
were tested for binding to ConC gp120 or ConC gp145 by ELISA. The percentage of antibody depleted was calculated using the following equation:
[1  (midpoint titer of plasma treated with gp120-coated beads/midpoint titer of plasma treated with blank beads)]  100. (B) Plasmas adsorbed
with ConC gp120 were tested for neutralizing activity against various envelope-pseudotyped viruses. The percent depletion was calculated as
follows: [1  (ID50 of plasma treated with gp120-coated beads/ID50 of plasma treated with blank beads)]  100. Data represent the means for two
separate neutralization experiments. (C) Plasmas adsorbed with ConC gp145 were tested for neutralizing activity against ConC and analyzed as
described for gp120.
FIG. 7. Epitope mapping of CAP177 and CAP255 anti-gp120 neutralizing antibodies. (A) The 3-year plasmas of these two participants were
adsorbed using gp120 mutated in the CD4 binding site (D368R) or coreceptor binding site (I420R) and gp120 with the V1V2 and V3 loops deleted
(core gp120). Wild-type gp120-coated beads and blank beads were used as positive and negative controls, respectively. Depleted plasmas were
tested for neutralization of ConC. (B) CAP177 plasma was adsorbed with V1V2- or V3-deleted gp120 prior to testing of ConC neutralization.
(C) Both plasmas were tested for neutralization against wild-type ConC and three mutants in the core DMR epitope. Data represent the means
for two separate neutralization experiments.
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not overlap these regions or at least are not affected by these
two mutations. However, use of a core gp120 in which the
V1V2 and V3 loops had been deleted affected the epitope
recognized by CAP177 but not that recognized by CAP255
(Fig. 7A and B), suggesting that elements present in the vari-
able loops were important for CAP177 neutralization. To de-
termine if these two samples targeted an epitope in the
gp120 core defined by the HJ16 MAb (7, 38), which also
overlaps the CD4 binding site, plasmas were tested for neu-
tralization of the DMR ConC mutants (D434A, M435A, or
R436A). None of these mutants showed reduced sensitivity
to the neutralizing antibodies in these 2 samples; in fact, the
D434A mutant was more sensitive to neutralization than the
wild-type virus (Fig. 7C).
A recent study reported a number of sites commonly tar-
geted by cross-neutralizing antibodies found in the plasmas of
HIV-1-infected individuals with neutralization breadth. These
included the N160 and L165 amino acids in the V2 region and
the N332 glycan at the base of the V3 loop (54). To assess
whether these types of antibodies were present in the cross-
neutralizing plasmas from the CAPRISA cohort, we tested the
3-year samples against single-point mutants made in either the
ConC or CAP45 background (Table 2). The introduction of
the N160A mutation into ConC reduced CAP8 neutralization
13-fold, with no decrease observed for any of the other sam-
ples. However, the same mutation in the CAP45 virus reduced
neutralization by CAP256 plasma 15-fold. In addition, CAP256
neutralization was sensitive to the L165A change in both ConC
and CAP45, with a 5-fold drop in titers. This site overlaps the
PG9/16 epitope (53). These observations, together with the
lack of binding to recombinant envelope proteins, suggested
the presence of PG9/16-like antibodies in these two plasmas.
Indeed, this proposition was further demonstrated in a recent
published detailed study on this participant (34). CAP177 titers
were reduced 3-fold with the introduction of an N332A muta-
tion in ConC, but this mutation did not affect neutralization by
any of the other 6 plasmas (Table 2). To confirm this, the same
mutation was also introduced into two other viruses. N332A mu-
tants of TRO.11 and Q23.17 were also resistant to neutralization
by CAP177 and, in addition, to CAP255 plasma. CAP206,
CAP248, and CAP257 plasmas showed no resistance to any of the
gp120 mutants tested. However, as mentioned above, CAP206
cross-neutralizing antibodies recognized predominantly the
MPER and the antibodies in subjects CAP248 and CAP257 were
largely dependent on epitopes that were apparent only on the
envelope trimer. A summary of the antibody specificities in these
7 plasma samples is shown in Table 2.
DISCUSSION
In this study, we established that after 3 years of infection,
the frequency of individuals with neutralization breadth in the
CAPRISA cohort was 17.5% (7/40 participants). In some in-
dividuals, cross-neutralizing antibodies appeared to target sub-
type-specific determinants, while in others these antibodies
were aimed at more universal epitopes. Heterologous neutral-
izing antibodies first appeared in some individuals as early as 1
year postinfection but peaked at 4 years, with no increases
thereafter. The number of viruses neutralized was associated
with the viral load and CD4 T cell count at set point (6
months postinfection) as well as with the drop in CD4 T cell
count between preinfection and 6 months, suggesting that early
events in HIV infection set the stage for the development of
breadth.
Broadly cross-neutralizing antibodies were produced in a
small proportion of individuals within the CAPRISA cohort
after 3 years of follow-up. The frequency and extent of neu-
tralization breadth found in this study were slightly lower than
those described in other studies, which reported up to 30% of
samples with this activity (9, 10, 16, 37, 44). However, many of
these other studies were cross-sectional studies that made use
of samples collected from chronic infections where the exact
duration of infection was not always available. Because of the
nature of the CAPRISA cohort, which is a prospective study of
HIV-negative individuals with documented seroconversion,
the timing and clinical features of infection are well known.
Furthermore, virus panels and sensitivities of various neutral-
ization assays vary considerably between studies, possibly con-
tributing to this difference. The availability of longitudinal viral
load data allowed us to analyze associations over time with the
development of breadth. Interestingly, only the set point viral
load at 6 months postinfection, not the overall antigenic stim-
ulation (as measured by viral load AUC), correlated with the
development of breadth. This agrees with a report by Pianta-
dosi and colleagues in which a multivariate analysis found the
set point, but not the contemporaneous viral load, to be asso-
TABLE 2. Effects of single point mutations on neutralization sensitivity and summary of antibody specificities
Plasma or
control MAb
















CAP206 1.0 1.0 0.1 1.0 0.9 1.8 0.7 MPER (14)
CAP177 0.9 NS 0.2 NS 3 4 >11 gp120, N332
CAP255 1.0 NS 0.1 NS 0.2 >3 >4 gp120 core, N332
CAP8 13 NS 0.9 NS 0.5 1.5 0.7 Quaternary, PG9/16-like
CAP248 1.4 0.9 0.2 1.0 0.4 1.1 2.1 Quaternary, unknown
CAP256 1.1 15 5 5 0.4 1.1 0.9 Quaternary, PG9/16-like (34)
CAP257 0.1 1.0 0.5 1.0 0.3 0.6 0.5 Quaternary, unknown
PG16 >1,000 >1,000 2.4 2 0.3 NS 1
2G12 NS NS NS NS NS 9 NS
a Calculated as wild-type ID50/mutant ID50 for the plasmas or as mutant IC50/wild-type IC50 for the MAbs. Changes in titer of 3-fold are shown in bold. NS,
wild-type virus not sensitive to plasma or MAb being tested.
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ciated with neutralization breadth (37). As they described, the
association of contemporaneous viral load and breadth ob-
served by them and others (37, 44) may have been driven by
the correlation of viral load within individuals at different
stages of infection. However, a high viral load is not an overall
predictor of neutralization breadth, as some highly viremic
individuals did not develop cross-neutralizing antibodies, even
after 5 years of infection. This has also been noticed in previ-
ous studies (10), suggesting that other factors in addition to
high viremia determine the development of breadth.
A low CD4 T cell count at set point was also found to
correlate with the development of cross-neutralizing antibod-
ies. Moreover, the drop in CD4 T cell count from preinfec-
tion to 6 months postinfection was a better predictor of the
extent of heterologous neutralization than the set point viral
load, despite the limited number of individuals in this analysis.
This association was noted in another study in which the CD4
T cell count at set point was also analyzed (10). It is intriguing
that a drop in CD4 T cell count was associated with the
production of cross-neutralizing antibodies given the impor-
tance of T cell help for B cell function. However, with the
lymphocytic choriomeningitis virus (LCMV) model, it has
been reported that depletion of CD4 T cells improves virus
neutralizing antibody production by reducing the CD4 T cell-
dependent virus-nonspecific polyclonal hyperglobulinemia (21,
40). HIV and hepatitis C virus infections, like LCMV infection,
induce similar dysfunctions (8, 19, 43), suggesting that deple-
tion of CD4 T cells in these infections might improve the
neutralizing antibody response by reducing B cell polyclonal
activation. This is an interesting observation and raises fur-
ther questions such as whether low CD4 T cell counts are
associated with a quicker upsurge and/or stronger autolo-
gous neutralizing responses, whether hyperglobulinemia is
lower in participants who develop cross-neutralizing anti-
bodies, and whether experimental depletion of CD4 T cells
in nonhuman primates may enhance the production of neu-
tralizing antibodies.
Our results suggest that neutralization breadth is acquired at
2 to 3 years postinfection. This agrees with a recent study done
with subtype B-infected individuals that showed that breadth
developed, on average, 2.5 years following infection (30). The
reason for the delay in the development of neutralization
breadth is not understood. However, the association of breadth
with high viral loads suggests that antigen-driven selection is
crucial in the development of these antibodies. This could
drive affinity maturation, as suggested in a study by Toran and
coworkers (48), who showed that all anti-gp120 neutralizing
antibodies in a long-term nonprogressor were clonally related,
with considerable somatic hypermutation. It has been pro-
posed that HIV-1 has evolved to avoid germ line-like antibody
recognition, possibly delaying the appearance of cross-neutral-
izing antibodies (57). Furthermore, immunogenetic analysis of
existing broadly neutralizing MAbs suggests that they have
undergone multiple rounds of affinity maturation to achieve
cross-neutralizing activity (36, 58). This is in contrast to other
virus infections, such as severe acute respiratory syndrome
(SARS) coronavirus and henipavirus infections, where cross-
neutralizing antibodies are induced early but carry very few
somatic mutations (39).
Our observation that no further increase in neutralization
breadth occurred after 4 years is particularly intriguing and
rather unexpected, although this was also recently reported for
the subtype B cohorts mentioned above (30). We hypothesized
that cross-neutralizing capacity would increase steadily over
time even after 4 years of infection. If neutralization breadth
occurs stochastically, with relentless waves of escape and the
development of new autologous neutralizing antibodies in the
presence of high antigenic loads resulting in the appearance of
antibodies that recognize a generally conserved epitope, then
this should happen at any stage of disease. Alternatively, dys-
regulation of the immune system over time (31) may result in
a reduced ability to mount new antibody responses at later
stages of infection. This is suggested by preliminary data from
our laboratory (data not shown) and by reports from others
that suggest that the capacity to mount new autologous re-
sponses is impaired after 2 to 3 years of infection, independent
of disease progression (49). However, this needs to be explored
further by measuring de novo autologous responses at various
times postinfection in individuals with a range of viral loads.
Interestingly, 5 of the 7 individuals identified here as having
cross-neutralizing activity were initiated on antiretroviral treat-
ment because they had low CD4 T cell counts and/or other
signs of clinical AIDS. Only CAP177 and CAP248 were still
ARV naive after 4 and 5 years of infection, respectively. This
observation is consistent with the report by Euler et al. that
cross-reactive antibodies do not protect against disease pro-
gression (10), probably because the virus readily escapes even
cross-neutralizing antibodies. Indeed, factors associated with
the development of neutralizing antibodies, such as high viral
load and low CD4 T cell count, are strongly correlated with
disease progression (12, 13, 29). These factors herald a decline
of immune function which, in the absence of successful anti-
retroviral therapy, results in progression to AIDS. It is possible
that the individuals with high viral loads and low CD4 T cell
counts who failed to mount a cross-neutralizing response
within this time frame “lost their opportunity” with the col-
lapse of the immune system. On the other hand, participants
with low viral loads and high CD4 T cell counts did not
develop breadth, probably due to a lack of sufficient antigenic
stimulation and/or the overwhelming nonspecific hyperglobu-
linemia. It would be interesting to explore whether these indi-
viduals develop breadth at later stages of infection, either as
waves of autologous neutralization continue to develop against
a diversifying virus or through a sudden collapse in control and
drop in CD4 T cell count that result in the development of
cross-neutralizing antibodies.
A summary of what is currently known about the antibody
specificities mediating breadth at 3 years postinfection in the 7
individuals in group 1 is shown in Table 2. Only one participant
had neutralizing antibodies against the MPER of gp41. These
plasma antibodies recognized an epitope centered on D674
and were shown to be distinct from other antibodies with
MPER specificities, such as 4E10 and Z13e1 (14). Confirma-
tion of this comes from the recent isolation of a neutralizing
MAb (CAP206-CH12), using circulating blood memory B cells
from CAP206, which showed similar epitope recognition (L.
Morris et al., unpublished data). Two participants had anti-
bodies that recognized epitopes in gp120 that involved the
glycan at position 332. However, these two specificities are
likely to be different from one another given that the CAP255
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epitope is present on the core gp120, while the CAP177 anti-
body depends on variable loops. Walker and colleagues also
found N332-dependent neutralizing antibodies in 5 of the 19
plasmas that they analyzed. Only one of these plasmas was
shown to have 2G12-like activity, despite their epitope conver-
gence on the N332 glycan (54). Antibodies targeting trimer-
specific epitopes were the most common among the 7 individ-
uals with neutralization breadth. Plasmas from two individuals,
CAP248 and CAP257, could not be mapped using available
methods. However, in two cases, CAP8 and CAP256, depen-
dence on the N160 glycan suggested the presence of PG9/16-
like antibodies. Although N160- and L165-dependent neutral-
ization has been described recently as two distinct specificities
(54), both affected neutralization by CAP256 plasma. The fine
mapping of the CAP256 quaternary specificity indicated that it
depended on various residues in the V2 loop which overlapped
the PG9/16 epitope (34).
Three of the four individuals whose antibodies recognized
quaternary neutralizing epitopes, i.e., CAP248, CAP256, and
CAP257, neutralized subtype C viruses preferentially, and this
discrimination was more evident at early time points. However,
CAP8 antibodies preferentially neutralized subtype B viruses.
In contrast, the anti-MPER antibodies in CAP206 and the
anti-gp120 antibodies conferring breadth in CAP177 and
CAP255 neutralized viruses from different subtypes equally.
Preferential intrasubtype neutralization was reported previ-
ously by van Gils and colleagues (50). In their study of subtype
B-infected individuals, participants with intermediate breadth
showed more subtype B-restricted responses, which suggested
that subtype specificity was related to low neutralization titers.
In contrast, CAP256 and CAP257, the two participants with
the greatest breadth, had high titers against subtype C viruses
despite their subtype specificity. Therefore, we concluded that
subtype-specific neutralization is not a general feature of in-
termediate breadth but instead depends on the epitope recog-
nized by the cross-neutralizing antibodies. Furthermore, our
data suggest that antibodies targeting quaternary neutralizing
epitopes are more likely to be subtype specific than those with
other targets.
The V1V2 and C3 regions have previously been shown to be
common targets for autologous neutralizing antibodies in sub-
type C infection (26, 33, 35, 42). It is interesting that most
heterologous activity found in this study overlapped with these
two regions. CAP8 and CAP256 plasmas contained cross-neu-
tralizing antibodies that recognized epitopes within the V2
loop, while CAP177 and CAP255 appeared to recognize an
epitope in C3. This suggests that the V1V2 and C3 regions are
particularly immunodominant regions of the envelope and are
the focus of the neutralizing antibody response from early
times on, with these type-specific antibodies sometimes devel-
oping into antibodies with cross-neutralizing specificities. On-
going studies in our laboratory aim to determine the relation-
ship between the evolution of autologous neutralizing
antibodies and the development of broadly neutralizing activ-
ity. Interestingly, the N332 glycan targeted by the heterologous
neutralizing antibodies in CAP177 was not present in the trans-
mitted founder virus isolated from this participant (1). This
glycan appeared later, at 6 months postinfection, as an escape
mutation driven by the primary autologous neutralizing anti-
body response that targeted the alpha-2 helix of C3 (35). This
suggests that, at least in this case, later variants rather than the
infecting virus elicited antibodies with cross-neutralizing activ-
ity. Elucidating the path between these two responses may
guide the design of immunization strategies that mimic this
process, focusing the response on the conserved motifs in the
envelope glycoprotein.
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